Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.60 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.60 |
| ▸ | SRC | P12931 | 2/20 | 0.60 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.60 |
| ▸ | DPP4 | P27487 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | GAPDH | P04406 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | STAT6 | P42226 | 1/20 | 0.60 |
| ▸ | PI4KA | P42356 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10689183 | 0.84 | ADORA3 (0.73) | ADORA1P2RY1SMN1; SMN2P2RY2ADORA3 | |
| SCHEMBL8606022 | 0.84 | ADORA1 (0.64) | ADORA1P2RY1SMN1; SMN2P2RY2ADORA3 | |
| SCHEMBL8607675 | 0.84 | ADORA1 (0.64) | ADORA1P2RY1SMN1; SMN2P2RY2ADORA3 | |
| SCHEMBL10604613 | 0.84 | ADORA1 (0.64) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL8606410 | 0.84 | ADORA1 (0.64) | ADORA1P2RY1SMN1; SMN2P2RY2ADORA3 | |
| SCHEMBL8606939 | 0.84 | ADORA1 (0.64) | ADORA1P2RY1SMN1; SMN2P2RY2ADORA3 | |
| SCHEMBL10605321 | 0.83 | PI4KA (0.62) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL7189749 | 0.83 | ADORA1 (0.59) | ADORA1P2RY1SMN1; SMN2P2RY2ADORA3 | |
| SCHEMBL7195835 | 0.83 | ADORA1 (0.59) | ADORA1P2RY1SMN1; SMN2P2RY2ADORA3 | |
| SCHEMBL120551 | 0.82 | ADORA3 (0.69) | ADORA1P2RY1SMN1; SMN2P2RY2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328577-A1 | THE TREATMENT OF HEARING LOSS | Auckland UniServices Limited (NZ) | 2011-06-08 | — | — | EP | claimed |
| EP-0291051-A2 | Individual isomers of endo-bicyclo[2.2.1]heptyl adenosine | WARNER-LAMBERT COMPANY (US) | 1988-11-17 | — | — | EP | claimed |
| EP-3247715-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | Inotek Pharmaceuticals Corporation (US) | 2017-11-29 | — | — | EP | disclosed |
| WO-2016090005-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | INOTEK PHARMACEUTICALS CORPORATION (US) | 2016-06-09 | — | — | WO | disclosed |
| EP-2968388-A1 | A METHOD OF PROVIDING OCULAR NEUROPROTECTION | Inotek Pharmaceuticals Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014152733-A1 | A METHOD OF PROVIDING OCULAR NEUROPROTECTION | INOTEK PHARMACEUTICALS CORPORATION (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-2555776-A1 | COMBINATION COMPOSITIONS OF ADENOSINE A1 AGONISTS AND NON-SELECTIVE BETA-ADRENERGIC RECEPTOR BLOCKERS FOR REDUCING INTRAOCULAR PRESSURE | Inotek Pharmaceuticals Corporation (US) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011116292-A1 | COMBINATION COMPOSITIONS OF ADENOSINE A1 AGONISTS AND NON-SELECTIVE BETA-ADRENERGIC RECEPTOR BLOCKERS FOR REDUCING INTRAOCULAR PRESSURE | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110207689-A1 | THE TREATMENT OF HEARING LOSS | AUCKLAND UNISERVICES LIMITED | 2011-08-25 | — | — | US | disclosed |
| US-20100009934-A1 | BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| EP-0689405-A4 | METHODS FOR PROTECTING TISSUES AND ORGANS FROM ISCHEMIC DAMAGE | GENSIA INC (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0689405-A1 | METHODS FOR PROTECTING TISSUES AND ORGANS FROM ISCHEMIC DAMAGE | GENSIA, INC. (US) | 1996-01-03 | — | — | EP | disclosed |
| WO-1994021195-A1 | METHODS FOR PROTECTING TISSUES AND ORGANS FROM ISCHEMIC DAMAGE | GENSIA, INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| US-5227485-A | Pyrazolo[3,4-d]pyrimidines with adenosine-like binding affinities | GRIFFITH UNIVERSITY (AU) | 1993-07-13 | — | — | US | disclosed |
| EP-0291051-A2 | Individual isomers of endo-bicyclo[2.2.1]heptyl adenosine | WARNER-LAMBERT COMPANY (US) | 1988-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207689-A1 | THE TREATMENT OF HEARING LOSS | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885P2RY1 9/4885SMN1; SMN2 3248/4885 |
| US-20100009934-A1 | BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ADRB1, ADRB2, ADRA2B | ADORA1 14/4885P2RY1 170/4885SMN1; SMN2 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.